Tinlarebant, an oral retinol-binding protein 4 (RBP4) inhibitor currently undergoing phase III testing in the DRAGON trial, has received FDA Breakthrough Therapy designation for Stargardt disease (STGD1) due to its ability to limit retinoid flux to the retina [180]. This evidence concerns the gene RBP4 and severe early-childhood-onset retinal dystrophy.